P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1264
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-37 a Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) With Docetaxel in PTS With Previously Treated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

P2.06-10 Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-42 AXL, C-Met and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.06-15 Malignant Pleural Mesothelioma in Young Adult People in Uganda

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy